Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected in Q2 2024.

Related Keywords

United States , American , Chiesi Farmaceutici , Inhibrx Biosciences Inc New , Inhibrx Inc , Inhibrx Biosciences Inc , New Inhibrx , Mark Lappe , North American ,